Theophylline in Dextrose

drug-information.ru

|Theophylline in Dextrose

Drugs search, click the first letter of a drug name:


| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9  Home

Theophylline in Dextrose


Generic Name: theophylline and dextrose monohydrate
Dosage Form: Injection

Flexible Plastic Container

Rx only

Theophylline in Dextrose Description

Theophylline is structurally classified as a methylxanthine. It occurs as a white, odorless, crystalline powder with a bitter taste. Anhydrous theophylline has the chemical name 1H-Purine-2,6-dione,3,7-dihydro-1,3-dimethyl-, and is represented by the following structural formula:

The molecular formula of anhydrous theophylline is C7H8N4O2 with a molecular weight of 180.17.

Dextrose, USP is chemically designated D-glucose, monohydrate (C6H12O6• H2O), a hexose sugar freely soluble in water. It has the following structural formula:

The molecular weight is 198.17.

Water for Injection, USP is chemically designated H2O.

Theophylline 200, 400 and 800 mg in 5% Dextrose Injection, USP are sterile, nonpyrogenic solutions of theophylline, anhydrous and dextrose in water for injection. See Table in HOW SUPPLIED for summary of contents and characteristics of these solutions.

The solutions contain no bacteriostatic, antimicrobial agent or added buffer and are intended only for use as a single-dose administration. When smaller doses are required, the unused portion should be discarded.

The flexible plastic container is fabricated from a specially formulated polyvinylchloride. Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. Solutions in contact with the plastic container may leach out certain of its chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period.

Theophylline in Dextrose - Clinical Pharmacology

Mechanism of Action:

Theophylline has two distinct actions in the airways of patients with reversible obstruction; smooth muscle relaxation (i.e., bronchodilation) and suppression of the response of the airways to stimuli (i.e., non-bronchodilator prophylactic effects). While the mechanisms of action of theophylline are not known with certainty, studies in animals suggest that bronchodilatation is mediated by the inhibition of two isozymes of phosphodiesterase (PDE III and, to a lesser extent, PDE IV), while nonbronchodilator prophylactic actions are probably mediated through one or more different molecular mechanisms, that do not involve inhibition of PDE III or antagonism of adenosine receptors. Some of the adverse effects associated with theophylline appear to be mediated by inhibition of PDE III (e.g., hypotension, tachycardia, headache, and emesis) and adenosine receptor antagonism (e.g., alterations in cerebral blood flow).

Theophylline increases the force of contraction of diaphragmatic muscles. This action appears to be due to enhancement of calcium uptake through an adenosine-mediated channel.

Serum Concentration-Effect Relationship:

Bronchodilation occurs over the serum theophylline concentration range of 5-20 mcg/mL. Clinically important improvement in symptom control and pulmonary function has been found in most studies to require serum theophylline concentrations >10 mcg/mL. At serum theophylline concentrations >20 mcg/mL, both the frequency and severity of adverse reactions increase. In general, maintaining the average serum theophylline concentration between 10 and 15 mcg/mL will achieve most of the drug’s potential therapeutic benefit while minimizing the risk of serious adverse events.

Pharmacokinetics:

Overview The pharmacokinetics of theophylline vary widely among similar patients and cannot be predicted by age, sex, body weight or other demographic characteristics. In addition, certain concurrent illnesses and alterations in normal physiology (see Table I) and co-administration of other drugs (see Table II) can significantly alter the pharmacokinetic characteristics of theophylline. Within-subject variability in metabolism has also been reported in some studies, especially in acutely ill patients.

It is, therefore, recommended that serum theophylline concentrations be measured frequently in acutely ill patients receiving intravenous theophylline (e.g., at 24-hr. intervals). More frequent measurements should be made during the initiation of therapy and in the presence of any condition that may significantly alter theophylline clearance (see PRECAUTIONS, Effects on Laboratory Tests).

Table I. Mean and range of total body clearance and half-life of theophylline related to age and altered physiological states.¶

Total body clearance*

Half-life

mean (range)††

mean (range)††

Population characteristics

(mL/kg/min)

(hr)

Age

Premature neonates

postnatal age 3-15 days

0.29 (0.09-0.49)

30 (17-43)

postnatal age 25-57 days

0.64 (0.04-1.2)

20 (9.4-30.6)

Term infants

postnatal age 1-2 days

NR

25.7 (25-26.5)

postnatal age 3-30 weeks

NR

11 (6-29)

Pediatric patients

1-4 years

1.7 (0.5-2.9)

3.4 (1.2-5.6)

4-12 years

1.6 (0.8-2.4)

NR

13-15 years

0.9 (0.48-1.3)

NR 

16-17 years

1.4 (0.2-2.6)

3.7 (1.5-5.9)

Adults (16-60 years)

otherwise healthy

nonsmoking asthmatics

0.65 (0.27-1.03)

8.7 (6.1-12.8)

Elderly (>60 years)

nonsmokers with normal cardiac,

liver, and renal function

0.41 (0.21-0.61)

9.8 (1.6-18)

Concurrent illness or

altered physiological state

Acute pulmonary edema

0.33** (0.07-2.45)

19** (3.1-8.2)

COPD- >60 years, stable

nonsmoker >1 year

0.54 (0.44-0.64)

11 (9.4-12.6)

COPD with cor pulmonale

0.48 (0.08-0.88)

NR

Cystic fibrosis (14-28 years)

1.25 (0.31-2.2)

6.0 (1.8-10.2)

Fever associated with acute viral respiratory

illness (pediatric patients 9-15 years)

NR

7.0 (1.0-13)

Liver disease- cirrhosis

0.31** (0.1-0.7)

32** (10-56)

acute hepatitis

0.35 (0.25-0.45)

19.2 (16.6-21.8)

cholestasis

0.65 (0.25-1.45)

14.4 (5.7-31.8)

Pregnancy- 1st trimester

NR 

8.5 (3.1-13.9)

2nd trimester

NR

8.8 (3.8-13.8)

3rd trimester

NR

13.0 (8.4-17.6)

Sepsis with multi-organ failure

0.47 (0.19-1.9)

18.8 (6.3-24.1)

Thyroid disease- hypothyroid

0.38 (0.13-0.57)

11.6 (8.2-25)

hyperthyroid

0.8 (0.68-0.97)

4.5 (3.7-5.6)

¶  For various North American patient populations from literature reports. Different rates of elimination and consequent dosage requirements have been observed among other peoples.

*  Clearance represents the volume of blood completely cleared of theophylline by the liver in one minute. Values listed were generally determined at serum theophylline concentrations < 20 mcg/mL; clearance may decrease and half-life may increase at higher serum concentrations due to non-linear pharmacokinetics.

††  Reported range or estimated range (mean ±2 SD) where actual range not reported.

  NR = not reported or not reported in a comparable format.

** Median

Note: In addition to the factors listed above, theophylline clearance is increased and half-life decreased by low carbohydrate/high protein diets, parenteral nutrition, and daily consumption of charcoal-broiled beef. A high carbohydrate/low protein diet can decrease the clearance and prolong the half-life of theophylline.

Distribution Once theophylline enters the systemic circulation, about 40% is bound to plasma protein, primarily albumin. Unbound theophylline distributes throughout body water, but distributes poorly into body fat. The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3-0.7 L/kg) based on ideal body weight. Theophylline passes freely across the placenta, into breast milk and into the cerebrospinal fluid (CSF). Saliva theophylline concentrations approximate unbound serum concentrations, but are not reliable for routine or therapeutic monitoring unless special techniques are used. An increase in the volume of distribution of theophylline, primarily due to reduction in plasma protein binding, occurs in premature neonates, patients with hepatic cirrhosis, uncorrected acidemia, the elderly and in women during the third trimester of pregnancy. In such cases, the patient may show signs of toxicity at total (bound + unbound) serum concentrations of theophyllinein the therapeutic range (10-20 mcg/mL) due to elevated concentrations of the pharmacologically active unbound drug. Similarly, a patient with decreased theophylline binding may have a subtherapeutic total drug concentration while the pharmacologically active unbound concentration is in the therapeutic range. If only total serum theophylline concentration is measured, this may lead to an unnecessary and potentially dangerous dose increase. In patients with reduced protein binding, measurement of unbound serum theophylline concentration provides a more reliable means of dosage adjustment than measurement of total serum theophylline concentration. Generally, concentrations of unbound theophylline should be maintained in the range of 6-12 mcg/mL.

Metabolism In adults and pediatric patients beyond one year of age, approximately 90% of the dose is metabolized in the liver. Biotransformation takes place through demethylation to 1-methylxanthine and 3-methylxanthine and hydroxylation to 1,3-dimethyluric acid. 1-methylxanthine is further hydroxylated, by xanthine oxidase, to 1-methyluric acid. About 6% of a theophylline dose is N-methylated to caffeine. Theophylline demethylation to 3-methylxanthine is catalyzed by cytochrome P-450 1A2, while cytochromes P-450 2E1 and P-450 3A3 catalyze the hydroxylation to 1,3-dimethyluric acid. Demethylation to 1-methylxanthine appears to be catalyzed either by cytochrome P-450 1A2 or a closely related cytochrome. In neonates, the N-demethylationpathway is absent while the function of the hydroxylation pathway is markedly deficient. The activity of these pathways slowly increases to maximal levels by one year of age.

Caffeine and 3-methylxanthine are the only theophylline metabolites with pharmacologic activity. 3-methylxanthine has approximately one tenth the pharmacologic activity of theophylline and serum concentrations in adults with normal renal function are <1 mcg/mL. In patients with end-stage renal disease, 3-methylxanthine may accumulate to concentrations that approximate the unmetabolized theophylline concentration. Caffeine concentrations are usually undetectable in adults regardless of renal function. In neonates, caffeine may accumulate to concentrations that approximate the unmetabolized theophylline concentration and thus, exert a pharmacologic effect.

Both the N-demethylation and hydroxylation pathways of theophylline biotransformation are capacity-limited. Due to the wide intersubject variability of the rate of theophylline metabolism, nonlinearity of elimination may begin in some patients at serum theophylline concentrations <10 mcg/mL. Since this nonlinearity results in more than proportional changes in serum theophylline concentrations with changes in dose, it is advisable to make increases or decreases in dose in small increments in order to achieve desired changes in serum theophylline concentrations (see DOSAGE AND ADMINISTRATION, Table VI). Accurate prediction of dose-dependency of theophylline metabolism in patients a priori is not possible, but patients with very high initial clearance rates (i.e., low steady state serum theophylline concentrations at above average doses) have the greatest likelihood of experiencing large changes in serum theophylline concentration in response to dosage changes.

Excretion In neonates, approximately 50% of the theophylline dose is excreted unchanged in the urine. Beyond the first three months of life, approximately 10% of the theophylline dose is excreted unchanged in the urine. The remainder is excreted in the urine mainly as 1,3-dimethyluric acid (35-40%), 1-methyluric acid (20-25%) and 3-methylxanthine (15-20%). Since little theophylline is excreted unchanged in the urine and since active metabolites of theophylline (i.e., caffeine, 3-methylxanthine) do not accumulate to clinically significant levels even in the face of end-stage renal disease, no dosage adjustment for renal insufficiency is necessary in adults and pediatric patients >3 months of age. In contrast, the large fraction of the theophylline dose excreted in the urine as unchanged theophylline and caffeine in neonates requires careful attention to dose reduction and frequent monitoring of serum theophylline concentrations in neonates with reduced renal function (see WARNINGS).

Serum Concentrations at Steady StateIn a patient who has received no theophylline in the previous 24 hours, a loading dose of intravenous theophylline of 4.6 mg/kg, calculated on the basis of ideal body weight and administered over 30 minutes, on average, will produce a maximum post-distribution serum concentration of 10 mcg/mL with a range of 6-16 mcg/mL. In nonsmoking adults, initiation of a constant intravenous theophylline infusion of 0.4 mg/kg/hr at the completion of the loading dose, on average, will result in a steady-state concentration of 10 mcg/mL with a range of 7-26 mcg/mL. The mean and range of steady-state serum concentrations are similar when the average pediatric patient (age 1 to 9 years) is given a loading dose of 4.6 mg/kg theophylline followed by a constant intravenous infusion of 0.8 mg/kg/hr. (See DOSAGE AND ADMINISTRATION.)

Special Populations (See Table I for mean clearance and half-life values)

Geriatrics The clearance of theophylline is decreased by an average of 30% in healthy elderly adults (>60 yrs.) compared to healthy young adults. Careful attention to dose reduction and frequent monitoring of serum theophylline concentrations are required in elderly patients (see WARNINGS).

Pediatrics The clearance of theophylline is very low in neonates (see WARNINGS). Theophylline clearance reaches maximal values by one year of age, remains relatively constant until about 9 years of age and then slowly decreases by approximately 50% to adult values at about age 16. Renal excretion of unchanged theophylline in neonates amounts to about 50% of the dose, compared to about 10% in children older than three months and in adults. Careful attention to dosage selection and monitoring of serum theophylline concentrations are required in pediatric patients (see WARNINGS and DOSAGE AND ADMINISTRATION).

Gender Gender differences in theophylline clearance are relatively small and unlikely to be of clinical significance. Significant reduction in theophylline clearance, however, has been reported in women on the 20th day of the menstrual cycle and during the third trimester of pregnancy.

Race Pharmacokinetic differences in theophylline clearance due to race have not been studied.

Renal Insufficiency Only a small fraction, e.g., about 10%, of the administered theophylline dose is excreted unchanged in the urine of children greater than three months of age and adults. Since little theophylline is excreted unchanged in the urine and since active metabolites of theophylline (i.e., caffeine, 3-methylxanthine) do not accumulate to clinically significant levels even in the face of end-stage renal disease, no dosage adjustment for renal insufficiency is necessary in adults and children >3 months of age. In contrast, approximately 50% of the administered theophylline dose is excreted unchanged in the urine in neonates. Careful attention to dose reduction and frequent monitoring of serum theophylline concentrations are required in neonates with decreased renal function (see WARNINGS).

Hepatic Insufficiency Theophylline clearance is decreased by 50% or more in patients with hepatic insufficiency (e.g., cirrhosis, acute hepatitis, cholestasis). Careful attention to dose reduction and frequent monitoring of serum theophylline concentrations are required in patients with reduced hepatic function (see WARNINGS).

Congestive Heart Failure (CHF) Theophylline clearance is decreased by 50% or more in patients with CHF. The extent of reduction in theophylline clearance in patients with CHF appears to be directly correlated to the severity of the cardiac disease. Since theophylline clearance is independent of liver blood flow, the reduction in clearance appears to be due to impaired hepatocyte function rather than reduced perfusion. Careful attention to dose reduction and frequent monitoring of serum theophylline concentrations are required in patients with CHF (see WARNINGS).

Smokers Tobacco and marijuana smoking appears to increase the clearance of theophylline by induction of metabolic pathways. Theophylline clearance has been shown to increase by approximately 50% in young adult tobacco smokers and by approximately 80% in elderly tobacco smokers compared to nonsmoking subjects. Passive smoke exposure has also been shown to increase theophylline clearance by up to 50%. Abstinence from tobacco smoking for one week causes a reduction of approximately 40% in theophylline clearance. Careful attention to dose reduction and frequent monitoring of serum theophylline concentrations are required in patients who stop smoking (see WARNINGS). Use of nicotine gum has been shown to have no effect on theophylline clearance.

Fever Fever, regardless of its underlying cause, can decrease the clearance of theophylline. The magnitude and duration of the fever appear to be directly correlated to the degree of decrease of theophylline clearance. Precise data are lacking, but a temperature of 39°C (102°F) for at least 24 hours is probably required to produce a clinically significant increase in serum theophylline concentrations. Careful attention to dose reduction and frequent monitoring of serum theophylline concentrations are required in patients with sustained fever (see WARNINGS).

Miscellaneous Other factors associated with decreased theophylline clearance include the third trimester of pregnancy, sepsis with multiple organ failure, and hypothyroidism. Careful attention to dose reduction and frequent monitoring of serum theophylline concentrations are required in patients with any of these conditions (see WARNINGS). Other factors associated with increased theophylline clearance include hyperthyroidism and cystic fibrosis.

Clinical Studies:

Inhaled beta-2 selective agonists and systemically administered corticosteroids are the treatments of first choice for management of acute exacerbations of asthma. The results of controlled clinical trials on the efficacy of adding intravenous theophylline to inhaled beta-2 selective agonists and systemically administered corticosteroids in the management of acute exacerbations of asthma have been conflicting. Most studies in patients treated for acute asthma exacerbations in an emergency department have shown that addition of intravenous theophylline does not produce greater bronchodilation and increases the risk of adverse effects. In contrast, other studies have shown that addition of intravenous theophylline is beneficial in the treatment of acute asthma exacerbations in patients requiring hospitalization, particularly in patients who are not responding adequately to inhaled beta-2 selective agonists.

In patients with chronic obstructive pulmonary disease (COPD), clinical studies have shown that theophylline decreases dyspnea, air trapping, the work of breathing, and improves contractility of diaphragmatic muscles with little or no improvement in pulmonary function measurements.

Indications and Usage for Theophylline in Dextrose

Intravenous theophylline is indicated as an adjunct to inhaled beta-2 selective agonists and systemically administered corticosteroids for the treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.

Contraindications

Theophylline is contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product.

Warnings

Concurrent Illness:

Theophylline should be used with extreme caution in patients with the following clinical conditions due to the increased risk of exacerbation of the concurrent condition:

Active peptic ulcer disease

Seizure disorders

Cardiac arrhythmias (not including bradyarrhythmias)

Conditions That Reduce Theophylline Clearance:

There are several readily identifiable causes of reduced theophylline clearance. If the infusion rate is not appropriately reduced in the presence of these risk factors, severe and potentially fatal theophylline toxicity can occur. Careful consideration must be given to the benefits and risks of theophylline use and the need for more intensive monitoring of serum theophylline concentrations in patients with the following risk factors:

Age

Neonates (term and premature)

Pediatric patients <1 year

Elderly (>60 years)

Concurrent Diseases

Acute pulmonary edema

Congestive heart failure

Cor pulmonale

Fever; ≥102° for 24 hours or more; or lesser temperature elevations for longer periods

Hypothyroidism

Liver disease; cirrhosis, acute hepatitis

Reduced renal function in infants < 3 months of age

Sepsis with multi-organ failure

Shock

Cessation of Smoking

Drug Interactions

Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin)(see PRECAUTIONS, Drug Interactions, Table II).

When Signs or Symptoms of Theophylline Toxicity Are Present:

Whenever a patient receiving theophylline develops nausea or vomiting, particularly repetitive vomiting, or other signs or symptoms consistent with theophylline toxicity (even if another cause may be suspected), the intravenous infusion should be stopped and a serum theophylline concentration measured immediately.

Dosage Increases:

Increases in the dose of intravenous theophylline should not be made in response to an acute exacerbation of symptoms unless the steady-state serum theophylline concentration is <10 mcg/mL.

As the rate of theophylline clearance may be dose-dependent (i.e., steady-state serum concentrations may increase disproportionately to the increase in dose), an increase in dose based upon a subtherapeutic serum concentration measurement should be conservative. In general, limiting infusion rate increases to about 25% of the previous infusion rate will reduce the risk of unintended excessive increases in serum theophylline concentration (see DOSAGE AND ADMINISTRATION, Table VI).

Precautions

General:

Careful consideration of the various interacting drugs and physiologic conditions that can alter theophylline clearance and require dosage adjustment should occur prior to initiation of theophylline therapy and prior to increases in theophylline dose (see WARNINGS).

Monitoring Serum Theophylline Concentrations:

Serum theophylline concentration measurements are readily available and should be used to determine whether the dosage is appropriate. Specifically, the serum theophylline concentration should be measured as follows:

  1. Before making a dose increase to determine whether the serum concentration is subtherapeutic in a patient who continues to be symptomatic.

  2. Whenever signs or symptoms of theophylline toxicity are present.

  3. Whenever there is a new illness, worsening of an existing concurrent illness or a change in the patient"s treatment regimen that may alter theophylline clearance (e.g., fever >102°F sustained for ≥24 hours, hepatitis, or drugs listed in Table II are added or discontinued).

In patients who have received no theophylline in the previous 24 hours, a serum concentration should be measured 30 minutes after completion of the intravenous loading dose to determine whether the serum concentration is <10 mcg/mL indicating the need for an additional loading dose, or >20 mcg/mL indicating the need to delay starting the constant IV infusion. Once the infusion is begun, a second measurement should be obtained after one expected half life (e.g., approximately 4 hours in pediatric patients age 1 to 9 years and 8 hours in nonsmoking adults; See Table I for the expected half life in additional patient populations). The second measurement should be compared to the first to determine the direction in which the serum concentration has changed. The infusion rate can then be adjusted before steady state is reached in an attempt to prevent an excessive or subtherapeutic theophylline concentration from being achieved.

If a patient has received theophylline in the previous 24 hours, the serum concentration should be measured before administering an intravenous loading dose to make sure that it is safe to do so. If a loading dose is not indicated (i.e., the serum theophylline concentration is ≥10 mcg/mL), a second measurement should be obtained as above at the appropriate time after starting the intravenous infusion. If, on the other hand, a loading dose is indicated (see DOSAGE AND ADMINISTRATION for guidance on selection of the appropriate loading dose), a second blood sample should be obtained after the loading dose and a third sample should be obtained one expected half life after starting the constant infusion to determine the direction in which the serum concentration has changed.

Once the above procedures related to initiation of intravenous theophylline infusion have been completed, subsequent serum samples for determination of theophylline concentration should be obtained at 24-hour intervals for the duration of the infusion. The theophylline infusion rate should be increased or decreased as appropriate based on the serum theophylline levels.

When signs or symptoms of theophylline toxicity are present, the intravenous infusion should be stopped and a serum sample for theophylline concentration should be obtained as soon as possible, analyzed immediately, and the result reported to the clinician without delay. In patients in whom decreased serum protein binding is suspected (e.g., cirrhosis, women during the third trimester of pregnancy), the concentration of unbound theophylline should be measured and the dosage adjusted to achieve an unbound concentration of 6-12 mcg/mL.

Saliva concentrations of theophylline cannot be used reliably to adjust dosage without special techniques.

Information for Patients

N/A

Effects on Laboratory Tests:

As a result of its pharmacological effects, theophylline at serum concentrations within the 10-20 mcg/mL range modestly increases plasma glucose (from a mean of 88 mg% to 98 mg%), uric acid (from a mean of 4 mg/dl to 6 mg/dl), free fatty acids (from a mean of 451 μE q/l to 800 μEq/l), total cholesterol (from a mean of 140 vs 160 mg/dl), HDL (from a mean of 36 to 50 mg/dl), HDL/LDL ratio (from a mean of 0.5 to 0.7), and urinary free cortisol excretion (from a mean of 44 to 63 mcg/24 hr). Theophylline at serum concentrations within the 10-20 mcg/mL range may also transiently decrease serum concentrations of triiodothyronine (144 before, 131 after one week and 142 ng/dl after 4 weeks of theophylline). The clinical importance of these changes should be weighed against the potential therapeutic benefit of theophylline in individual patients.

Drug Interactions:

Theophylline interacts with a wide variety of drugs. The interaction may be pharmacodynamic, i.e., alterations in the therapeutic response to theophylline or another drug or occurrence of adverse effects without a change in serum theophylline concentration. More frequently, however, the interaction is pharmacokinetic, i.e., the rate of theophylline clearance is altered by another drug resulting in increased or decreased serum theophylline concentrations. Theophylline only rarely alters the pharmacokinetics of other drugs.

The drugs listed in Table II have the potential to produce clinically significant pharmacodynamic or pharmacokinetic interactions with theophylline. The information in the “Effect” column of Table II assumes that the interacting drug is being added to a steady-state theophylline regimen. If theophylline is being initiated in a patient who is already taking a drug that inhibits theophylline clearance (e.g., cimetidine, erythromycin), the dose of theophylline required to achieve a therapeutic serum theophylline concentration will be smaller. Conversely, if theophylline is being initiated in a patient who is already taking a drug that enhances theophylline clearance (e.g., rifampin), the dose of theophylline required to achieve a therapeutic serum theophylline concentration will be larger. Discontinuation of a concomitant drug that increases theophylline clearance will result in accumulation of theophylline to potentially toxic levels, unless the theophylline dose is appropriately reduced. Discontinuation of a concomitant drug that inhibits theophylline clearance will result in decreased serum theophylline concentrations, unless the theophylline dose is appropriately increased.

The drugs listed in Table III have either been documented not to interact with theophylline or do not produce a clinically significant interaction (i.e.,<15% change in theophylline clearance).

The listing of drugs in Tables II and III are current as of September 1, 1995. New interactions are continuously being reported for theophylline, especially with new chemical entities. The clinician should not assume that a drug does not interact with theophylline if it is not listed in Table II. Before addition of a newly available drug in a patient receiving theophylline, the package insert of the new drug and/or the medical literature should be consulted to determine if an interaction between the new drug and theophylline has been reported.

Table II. Clinically significant drug interactions with theophylline*.

Drug

Type of Interaction

Effect**

Adenosine

Theophylline blocks adenosine receptors.

Higher doses of adenosine may be required to achieve desired effect.

Alcohol

A single large dose of alcohol (3 mL/kg of whiskey) decreases theophylline clearance for up to 24 hours.

30% increase

Allopurinol

Decreases theophylline clearance at allopurinol doses ≥ 600 mg/day.

25% increase

Aminoglutethimide

Increases theophylline clearance by induction of microsomal enzyme activity.

25% decrease

Carbamazepine

Similar to aminoglutethimide.

30% decrease

Cimetidine

Decreases theophylline clearance by inhibiting cytochrome P450 1A2.

70% increase

Ciprofloxacin

Similar to cimetidine.

40% increase

Clarithromycin

Similar to erythromycin.

25% increase

Diazepam

Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors.

Larger diazepam doses may be required to produce desired level of sedation. Discontinuation of theophylline without reduction of diazepam dose may result in respiratory depression.

Disulfiram

Decreases theophylline clearance by inhibiting hydroxylation and

50% increase

demethylation.

Enoxacin

Similar to cimetidine.

300% increase

Ephedrine

Synergistic CNS effects.

Increased frequency of nausea, nervousness, and insomnia.

Erythromycin

Erythromycin metabolite decreases theophylline clearance by inhibiting cytochrome P450 3A3.

35% increase. Erythromycin steady-state serum concentrations decrease by a similar amount.

Estrogen

Estrogen containing oral contraceptives decrease theophylline clearance in a dose-dependent fashion. The effect of progesterone on theophylline clearance is unknown.

30% increase

Flurazepam

Similar to diazepam.

Similar to diazepam.

Fluvoxamine

Similar to cimetidine.

Similar to cimetidine.

Halothane

Halothane sensitizes the myocardium to catecholamines, theophylline increases release of endogenous catecholamines

Increased risk of ventricular arrhythmias.

Interferon, human recombinant alpha-A

Decreases theophylline clearance.

100% increase

Isoproterenol (IV)

Increases theophylline clearance.

20% decrease

Ketamine

Pharmacologic

May lower theophylline seizure threshold.

Lithium

Theophylline increases renal lithium clearance.

Lithium dose required to achieve a therapeutic serum concentration increased an average of 60%.

Lorazepam

Similar to diazepam.

Similar to diazepam.

Methotrexate (MTX)

Decreases theophylline clearance.

20% increase after low dose MTX, higher dose MTX may have a greater effect.

Mexiletine

Similar to disulfiram.

80% increase

Midazolam

Similar to diazepam.

Similar to diazepam.

Moricizine

Increases theophylline clearance.

25% decrease

Pancuronium

Theophylline may antagonize non-depolarizing neuromuscular blocking effects; possibly due to phosphodiesterase inhibition.

Larger dose of pancuronium may be required to achieve neuromuscular blockade.

Pentoxifylline

Decreases theophylline clearance.

30% increase

Phenobarbital

Similar to aminoglutethimide.

25% decrease after two weeks of concurrent Phenobarbital.

Phenytoin

Phenytoin increases theophylline clearance by increasing microsomal enzyme activity. Theophylline decreases phenytoin absorption.

Serum theophylline and phenytoin concentrations decrease about 40%.

Propafenone

Decreases theophylline clearance and pharmacologic interaction.

40% increase. Beta-2 blocking effect may decrease efficacy of theophylline.

Propranolol

Similar to cimetidine and pharmacologic interaction.

100% increase. Beta-2 blocking effect may decrease efficacy of theophylline.

Rifampin

Increases theophylline clearance by increasing cytochrome P450 1A2 and

20-40% decrease

3A3 activity.

Sulfinpyrazone

Increases theophylline clearance by increasing demethylation and

20% decrease

hydroxylation. Decreases renal clearance of theophylline.

Tacrine

Similar to cimetidine, also increases renal clearance of theophylline.

90% increase

Thiabendazole

Decreases theophylline clearance.

190% increase

Ticlopidine

Decreases theophylline clearance.

60% increase

Troleandomycin

Similar to erythromycin.

33-100% increase depending on troleandomycin dose.

Verapamil

Similar to disulfiram.

20% increase

* Refer to PRECAUTIONS, Drug Interactions for further information regarding table.

**  Average effect on steady state theophylline concentration or other clinical effect for pharmacologic interactions. Individual patients may experience larger changes in serum theophylline concentration than the value listed.

Table III. Drugs that have been documented not to interact with theophylline or drugs

that produce no clinically significant interaction with theophylline.*

albuterol,

lomefloxacin

systemic and inhaled

mebendazole

amoxicillin

medroxyprogesterone

ampicillin,

methylprednisolone

with or without sulbactam

metronidazole

atenolol

metoprolol

azithromycin

nadolol

caffeine,

nifedipine

dietary ingestion

nizatidine

cefaclor

norfloxacin

co-trimoxazole

ofloxacin

(trimethoprim and

omeprazole

sulfamethoxazole)

prednisone, prednisolone

diltiazem

ranitidine

dirithromycin

rifabutin

enflurane

roxithromycin

famotidine

sorbitol

felodipine

(purgative doses do not

Table III. Drugs that have been documented not to interact with theophylline or drugs that produce no clinically significant interaction with theophylline.* (Con’t.)

finasteride

inhibit theophylline

hydrocortisone

absorption)

isoflurane

sucralfate

isoniazid

terbutaline, systemic

isradipine

terfenadine

influenza vaccine

tetracycline

ketoconazole

tocainide

* Refer to PRECAUTIONS, Drug Interactions for information regarding table.

The Effect of Other Drugs on Theophylline Serum Concentration Measurements:

Most serum theophylline assays in clinical use are immunoassays which are specific for theophylline. Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays. Some drugs (e.g., cefazolin, cephalothin), however, may interfere with certain HPLC techniques. Caffeine and xanthine metabolites in neonates or patients with renal dysfunction may cause the reading from some dry reagent office methods to be higher than the actual serum theophylline concentration.

Carcinogenesis, Mutagenesis, and Impairment of Fertility:

Long term carcinogenicity studies have been carried out in mice (oral doses 30 - 150 mg/kg) and rats (oral doses 5 - 75 mg/kg). Results are pending.

Theophylline has been studied in Ames salmonella, in vivo and in vitro cytogenetics, micronucleus and Chinese hamster ovary test systems and has not been shown to be genotoxic.

In a 14 week continuous breeding study, theophylline, administered to mating pairs of B6C3F1 mice at oral doses of 120, 270 and 500 mg/kg (approximately 1.0 - 3.0 times the human dose on a mg/m2 basis) impaired fertility, as evidenced by decreases in the number of live pups per litter, decreases in the mean number of litters per fertile pair, and increases in the gestation period at the high dose as well as decreases in the proportion of pups born alive at the mid and high dose. In 13 week toxicity studies, theophylline was administered to F344 rats and B6C3F1 mice at oral doses of 40 - 300 mg/kg (approximately 2.0 times the human dose on a mg/m2 basis). At the high dose, systemic toxicity was observed in both species including decreases in testicular weight.

Pregnancy: CATEGORY C:

There are no adequate and well controlled studies in pregnant women. Additionally, there are no teratogenicity studies in non-rodents (e.g., rabbits). Theophylline was not shown to be teratogenic in CD-1 mice at oral doses up to 400 mg/kg, approximately 2.0 times the human dose on a mg/m2 basis or in CD-1 rats at oral doses up to 260 mg/kg, approximately 3.0 times the recommended human dose on a mg/m2 basis. At a dose of 220 mg/kg, embryotoxicity was observed in rats in the absence of maternal toxicity.

Nursing Mothers:

Theophylline is excreted into breast milk and may cause irritability or other signs of mild toxicity in nursing human infants. The concentration of theophylline in breast milk is about equivalent to the maternal serum concentration. An infant ingesting a liter of breast milk containing 10-20 mcg/mL of theophylline per day is likely to receive 10-20 mg of theophylline per day. Serious adverse effects in the infant are unlikely unless the mother has toxic serum theophylline concentrations.

Pediatric Use:

Theophylline is safe and effective for the approved indications in pediatric patients (see INDICATIONS AND USAGE). The constant infusion rate of intravenous theophylline must be selected with caution in pediatric patients since the rate of theophylline clearance is highly variable across the age range of neonates to adolescents (see CLINICAL PHARMACOLOGY, Table I, WARNINGS, and DOSAGE AND ADMINISTRATION, Table V). Due to the immaturity of theophylline metabolic pathways in children under the age of one year, particular attention to dosage selection and frequent monitoring of serum theophylline concentrations are required when theophylline is prescribed to pediatric patients in this age group.

Geriatric Use:

Elderly patients are at significantly greater risk of experiencing serious toxicity from theophylline than younger patients due to pharmacokinetic and pharmacodynamic changes associated with aging. Theophylline clearance is reduced in patients greater than 60 years of age, resulting in increased serum theophylline concentrations in response to a given theophylline infusion rate. Protein binding may be decreased in the elderly resulting in a larger proportion of the total serum theophylline concentration in the pharmacologically active unbound form. Elderly patients also appear to be more sensitive to the toxic effects of theophylline after chronic overdosage than younger patients. For these reasons, the maximum infusion rate of theophylline in patients greater than 60 years of age ordinarily should not exceed 17 mg/hr. unless the patient continues to be symptomatic and the steady state serum theophylline concentration is < 10 mcg/mL (see DOSAGE AND ADMINISTRATION). Theophylline infusion rates greater than 17 mg/hr. should be prescribed with caution in elderly patients.

Adverse Reactions

Adverse reactions associated with theophylline are generally mild when serum theophylline concentrations are < 20 mcg/mL and mainly consist of transient caffeine-like adverse effects such as nausea, vomiting, headache, and insomnia. When serum theophylline concentrations exceed 20 mcg/mL, however, theophylline produces a wide range of adverse reactions including persistent vomiting, cardiac arrhythmias, and intractable seizures which can be lethal (see OVERDOSAGE).

Other adverse reactions that have been reported at serum theophylline concentrations < 20 mcg/mL include diarrhea, irritability, restlessness, fine skeletal muscle tremors, and transient diuresis. In patients with hypoxia secondary to COPD, multifocal atrial tachycardia and flutter have been reported at serum theophylline concentrations≥ 15 mcg/mL. There have been a few isolated reports of seizures at serum theophylline concentrations < 20 mcg/mL in patients with an underlying neurological disease or in elderly patients. The occurrence of seizures in elderly patients with serum theophylline concentrations < 20 mcg/mL may be secondary to decreased protein binding resulting in a larger proportion of the total serum theophylline concentration in the pharmacologically active unbound form. The clinical characteristics of the seizures reported in patients with serum theophylline concentrations < 20 mcg/mL have generally been milder than seizures associated with excessive serum theophylline concentrations resulting from an overdose (i.e., they have generally been transient, often stopped without anticonvulsant therapy, and did not result in neurological residua).

Table IV. Manifestations of theophylline toxicity.*

Percentage of patients reported

with sign or symptom

Acute Overdose

Chronic Overdosage

(Large Single Ingestion)

(Multiple Excessive Doses)

Study 1

Study 2

Study 1

Study 2

Sign/Symptom

(n=157)

(n=14)

(n=92)

(n=102)

Asymptomatic

NR**

0

NR**

6

Gastrointestinal

Vomiting

73

93

30

61

Abdominal Pain

NR**

21

NR**

12

Diarrhea

NR**

0

NR**

14

Hematemesis

NR**

0

NR**

2

Metabolic/Other

Hypokalemia

85

79

44

43

Hyperglycemia

98

NR**

18

NR**

Acid/base disturbance

34

21

9

5

Rhabdomyolysis

NR**

7

NR**

0

Cardiovascular

Sinus tachycardia

100

86

100

62

Other supraventricular

2

21

12

14

tachycardias

Ventricular premature beats

3

21

10

19

Atrial fibrillation or flutter

1

NR**

12

NR**

Multifocal atrial tachycardia

0

NR**

2

NR**

Ventricular arrhythmias with

7

14

40

0

hemodynamic instability

Hypotension/shock

NR**

21

NR**

8

Neurologic

Nervousness

NR**

64

NR**

21

Tremors

38

29

16

14

Disorientation




Where can I get more information about Theophylline in Dextrose ? We recommend to use www.Drugs.com

Typical mistypes for Theophylline in Dextrose
rheophylline in dextrose, fheophylline in dextrose, gheophylline in dextrose, yheophylline in dextrose, 6heophylline in dextrose, 5heophylline in dextrose, tgeophylline in dextrose, tbeophylline in dextrose, tneophylline in dextrose, tjeophylline in dextrose, tueophylline in dextrose, tyeophylline in dextrose, thwophylline in dextrose, thsophylline in dextrose, thdophylline in dextrose, throphylline in dextrose, th4ophylline in dextrose, th3ophylline in dextrose, theiphylline in dextrose, thekphylline in dextrose, thelphylline in dextrose, thepphylline in dextrose, the0phylline in dextrose, the9phylline in dextrose, theoohylline in dextrose, theolhylline in dextrose, theo-hylline in dextrose, theo0hylline in dextrose, theopgylline in dextrose, theopbylline in dextrose, theopnylline in dextrose, theopjylline in dextrose, theopuylline in dextrose, theopyylline in dextrose, theophtlline in dextrose, theophglline in dextrose, theophhlline in dextrose, theophulline in dextrose, theoph7lline in dextrose, theoph6lline in dextrose, theophykline in dextrose, theophypline in dextrose, theophyoline in dextrose, theophylkine in dextrose, theophylpine in dextrose, theophyloine in dextrose, theophyllune in dextrose, theophylljne in dextrose, theophyllkne in dextrose, theophyllone in dextrose, theophyll9ne in dextrose, theophyll8ne in dextrose, theophyllibe in dextrose, theophyllime in dextrose, theophyllije in dextrose, theophyllihe in dextrose, theophyllinw in dextrose, theophyllins in dextrose, theophyllind in dextrose, theophyllinr in dextrose, theophyllin4 in dextrose, theophyllin3 in dextrose, theophylline un dextrose, theophylline jn dextrose, theophylline kn dextrose, theophylline on dextrose, theophylline 9n dextrose, theophylline 8n dextrose, theophylline ib dextrose, theophylline im dextrose, theophylline ij dextrose, theophylline ih dextrose, theophylline in sextrose, theophylline in xextrose, theophylline in cextrose, theophylline in fextrose, theophylline in rextrose, theophylline in eextrose, theophylline in dwxtrose, theophylline in dsxtrose, theophylline in ddxtrose, theophylline in drxtrose, theophylline in d4xtrose, theophylline in d3xtrose, theophylline in deztrose, theophylline in dectrose, theophylline in dedtrose, theophylline in destrose, theophylline in dexrrose, theophylline in dexfrose, theophylline in dexgrose, theophylline in dexyrose, theophylline in dex6rose, theophylline in dex5rose, theophylline in dexteose, theophylline in dextdose, theophylline in dextfose, theophylline in dexttose, theophylline in dext5ose, theophylline in dext4ose, theophylline in dextrise, theophylline in dextrkse, theophylline in dextrlse, theophylline in dextrpse, theophylline in dextr0se, theophylline in dextr9se, theophylline in dextroae, theophylline in dextroze, theophylline in dextroxe, theophylline in dextrode, theophylline in dextroee, theophylline in dextrowe, theophylline in dextrosw, theophylline in dextross, theophylline in dextrosd, theophylline in dextrosr, theophylline in dextros4, theophylline in dextros3, heophylline in dextrose, teophylline in dextrose, thophylline in dextrose, thephylline in dextrose, theohylline in dextrose, theopylline in dextrose, theophlline in dextrose, theophyline in dextrose, theophyline in dextrose, theophyllne in dextrose, theophyllie in dextrose, theophyllin in dextrose, theophyllinein dextrose, theophylline n dextrose, theophylline i dextrose, theophylline indextrose, theophylline in extrose, theophylline in dxtrose, theophylline in detrose, theophylline in dexrose, theophylline in dextose, theophylline in dextrse, theophylline in dextroe, theophylline in dextros, hteophylline in dextrose, tehophylline in dextrose, thoephylline in dextrose, thepohylline in dextrose, theohpylline in dextrose, theopyhlline in dextrose, theophlyline in dextrose, theophylilne in dextrose, theophyllnie in dextrose, theophyllien in dextrose, theophyllin ein dextrose, theophyllinei n dextrose, theophylline ni dextrose, theophylline i ndextrose, theophylline ind extrose, theophylline in edxtrose, theophylline in dxetrose, theophylline in detxrose, theophylline in dexrtose, theophylline in dextorse, theophylline in dextrsoe, theophylline in dextroes, ttheophylline in dextrose, thheophylline in dextrose, theeophylline in dextrose, theoophylline in dextrose, theopphylline in dextrose, theophhylline in dextrose, theophyylline in dextrose, theophyllline in dextrose, theophyllline in dextrose, theophylliine in dextrose, theophyllinne in dextrose, theophyllinee in dextrose, theophylline in dextrose, theophylline iin dextrose, theophylline inn dextrose, theophylline in dextrose, theophylline in ddextrose, theophylline in deextrose, theophylline in dexxtrose, theophylline in dexttrose, theophylline in dextrrose, theophylline in dextroose, theophylline in dextrosse, theophylline in dextrosee, etc.



© Copyright by drug-information.ru 2001-2019. All rights reserved